Clinical Trial

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

Name: Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies — clinical trial record (NCT06758713)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a single center, open-label, dose-escalation/expansion clinical study to evaluate the safety and effectiveness of Fourth-Generation CAR-T, and determine the recommended dose of the CAR T-cells for patients with Multiple Myeloma，B-cell lymphoma and other hematologic malignancies.

Trial Details

NCT Number	NCT06758713
Lead Sponsor	The Third Affiliated Hospital of Southern Medical University
Conditions	Multiple Myeloma, B-cell Lymphoma, Hematological Malignancy
Enrollment	60 participants
Start Date	2025-01-15
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-01-06